Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 24, 2020
Daily News
March 24, 2020
- Novartis Japan to Shed Oncology Staffers amid Overall Downscaling
March 24, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
- Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
- Chugai, Roche, Genentech File Patent Suit against Fresenius Kabi over Alecensa
March 24, 2020
- KM Biologics, Takeda to Wind Up Sales Partnership on Flu Vaccine
March 24, 2020
- Mochida, Gene Techno Science Pair Up for Regenerative Medicines for Rare Gastrointestinal Diseases
March 24, 2020
- Takeda’s Entyvio Approved in China
March 24, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…